← Leaderboards
Kingshuk Das
University Of California Los Angeles
$73,689
Attributed
$368,446
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $184.2K · FY2017–18$200K$150K$100K$50K$0
'17
'18
Funding mix
By agency
NIH$368,446 · 1
By mechanism
UH2$368,446 · 1
Top collaborators
- David S Chia2 shared
- Guy Soo Hoo2 shared
- Fang Wei2 shared
- David T Wong2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Johannes Czernin$5,995,082
- Caius Gabriel Radu$8,088,566
- David T Wong$54,826,713
- Holden H Wu$4,936,760
- David S Chia$9,399,833
Others in their field
Other Emerging Leaders on “Actionable Mutation”
- Erin Rooney Riggs · Broad Institute, Inc.$6,471,349
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$6,328,779
- Thomas Dick · Rbhs-New Jersey Medical School$5,970,903
- Brian Liau · Harvard University$4,574,123
- Christine Ladd-Acosta · Johns Hopkins University$4,560,160
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$4,505,832
Research focus
Actionable MutationAdenocarcinomaAmendmentAmericanAmerican Society Of Clinical OncologyAsiaBaseBiopsyBlindedCancer CareCancer CellCancer DetectionCancer PatientC-Erbb-1 Proto-OncogenesChemotherapyClinicClinical DevelopmentClinical PracticeClinical ResearchClinical Research SiteCollegeCostCountryAccreditation
Grant awards (2)
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2018 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2017 · CA